Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling. [PDF]
Alomari G +9 more
europepmc +1 more source
The efficacy and safety of 1470 nm diode laser in the treatment of benign prostatic hyperplasia: a prospective, multicenter study. [PDF]
Xu H +7 more
europepmc +1 more source
Diversity of Gut Microbiota and Metabolites in Benign Prostatic Hyperplasia with Different Prostate Volumes. [PDF]
Liu J +12 more
europepmc +1 more source
A Case Series on the Efficacy and Safety of Transperineal Laser Ablation for Benign Prostatic Hyperplasia. [PDF]
Locke MR, Locke DR.
europepmc +1 more source
Predictors and predictive performance of immune-inflammation indices for symptom severity in benign prostatic hyperplasia. [PDF]
Kassaw AB, Abdu SM, Abebe G.
europepmc +1 more source
Four-year outcomes of water vapor thermal therapy for benign prostatic hyperplasia. [PDF]
Higazy A +6 more
europepmc +1 more source
Low-dose finasteride in benign prostatic hyperplasia: a comprehensive narrative review of efficacy, safety, and preventative potential. [PDF]
Farooqi M +3 more
europepmc +1 more source
The gut-prostate axis in benign prostatic hyperplasia: systematic review of microbial dysbiosis and pathogenic mechanisms. [PDF]
Xu Y +5 more
europepmc +1 more source
Local and Systemic Effects of Chronic Intracavernous Injection of Papaverine, Prostaglandine E1 and Saline in Primates [PDF]
Aboseif, Sherif R. +7 more
core
Effect of circadian rhythm disruption on benign prostatic hyperplasia in rats. [PDF]
Huang X, Tang X, Xu Y, Liu Z, Luo G.
europepmc +1 more source

